4564.T OncoTherapy (JPX) JPY 23.00 Mar 2026 Market Closed: most active by volume

The 4564.T stock finished Market Closed on 16 Mar 2026 at JPY 23.00, led the session in activity with 81,508,600.00 shares traded. That volume was 1.88x average and pushed the share price between a day low JPY 22.00 and day high JPY 23.00. OncoTherapy Science, Inc. (JPX) is drawing investor attention today on the back of clinical pipeline updates and unusually high turnover in Japan’s Healthcare group.

Trading snapshot: 4564.T stock activity

OncoTherapy Science, Inc. (4564.T) closed at JPY 23.00 on JPX with volume 81,508,600.00 versus an avgVolume 40,665,555.00, giving a relative volume of 1.88. Market cap is JPY 7,560,159,178.00 on 343,643,599.00 shares outstanding. The stock range today was JPY 22.00–23.00, year high JPY 35.00 and year low JPY 19.00. The picture shows active trading interest rather than a large directional move today.

Fundamentals and valuation: 4564.T stock financials

OncoTherapy is loss-making with EPS -2.83 and a negative PE of -7.77, reflecting recent net losses. Key ratios show PB 3.71 and price-to-sales 9.64, indicating premium pricing relative to current sales. The company holds cash per share JPY 6.06, a current ratio 8.51, and invests heavily in R&D (R&D to revenue 65.79%), consistent with a biotech development profile.

Technical picture: 4564.T stock momentum and indicators

Technically the stock shows short-term strength: RSI 69.45, MACD histogram 0.28, and CCI 205.80. Price sits above the 50-day average (Price Avg 50 JPY 21.06) and slightly below the 200-day average (Price Avg 200 JPY 23.90). Bollinger Bands (middle JPY 21.00) and ATR 1.39 suggest reduced immediate downside but indicators flag overbought momentum, so volatility can quicken.

Clinical pipeline and catalysts: 4564.T stock news drivers

OncoTherapy’s pipeline drives valuation: S-588410 is in Phase III for esophageal cancer, S-488210 in Phase I/II for head and neck cancer, and small molecules OTS167/OTS964 are in early clinical stages. Upcoming earnings on 2026-05-11 and any trial readouts or regulatory steps will move sentiment and liquidity. Company details are available at the official site source.

Meyka AI rates 4564.T with a score out of 100

Meyka AI rates 4564.T with a score out of 100: 69.34 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating balances strong cash reserves and R&D pipeline against negative profitability and valuation. Grades are model outputs and not financial advice.

Risks and opportunities for 4564.T stock

Risk drivers include clinical trial failure, continued operating losses, and potential equity dilution despite current strong turnover. Shares outstanding are 343,643,599.00, which raises dilution sensitivity on financings. Opportunities include a successful Phase III readout for S-588410 and license deals that could materially re-rate the stock. Healthcare sector performance in Japan is modest YTD, so sector tailwinds are limited but available for positive trial news.

Final Thoughts

Key takeaways for the 4564.T stock: today’s session closed at JPY 23.00 with outsized volume 81,508,600.00, signalling heightened trader interest on JPX in Japan’s Healthcare group. Fundamentals show heavy R&D spending, EPS -2.83, and a premium valuation (PB 3.71, P/S 9.64). Meyka AI’s forecast model projects a yearly price JPY 17.31, implying a downside of -24.73% versus the current price JPY 23.00, and a monthly model figure of JPY 16.61 (-27.78%). These forecasts are model-based projections and not guarantees. For active traders the pattern is short-term momentum with overbought indicators; for longer-term investors the outcome hinges on clinical milestones and funding. Use the upcoming 2026-05-11 earnings date and any trial updates as decision points, and consider position sizing given trial risk and share count. Meyka AI provides this analysis as an AI-powered market analysis platform, and these outputs are informational only, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.